top
Please input keywords
Order
*Country
United States
China
France
Germany
Netherlands
United Kingdom
Japan
South Korea
Israel
Australia
Hong Kong, China
New Zealand
Russia
Singapore
Taiwan, China
India
Aland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua & Barbuda
Argentina
Armenia
Aruba
Ascension Island
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
British Indian Ocean Territory
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Canary Islands
Cape Verde
Caribbean Netherlands
Cayman Islands
Central African Republic
Ceuta & Melilla
Chad
Chile
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo - Brazzaville
Congo - Kinshasa
Cook Islands
Costa Rica
Côte d’Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czechia
Denmark
Diego Garcia
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
Indonesia
Iran
Iraq
Ireland
Isle of Man
Italy
Jamaica
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau, China
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
New Caledonia
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territories
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Islands
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Rwanda
Samoa
San Marino
São Tomé & Príncipe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia & South Sandwich Islands
South Sudan
Spain
Sri Lanka
St. Barthélemy
St. Helena
St. Kitts & Nevis
St. Lucia
St. Martin
St. Pierre & Miquelon
St. Vincent & Grenadines
Sudan
Suriname
Svalbard & Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad & Tobago
Tristan da Cunha
Tunisia
Turkey
Turkmenistan
Turks & Caicos Islands
Tuvalu
U.S. Outlying Islands
U.S. Virgin Islands
Uganda
Ukraine
United Arab Emirates
United Nations
Uruguay
Uzbekistan
Vanuatu
Vatican City
Venezuela
Vietnam
Wallis & Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hANGPTL4 mice plus
Strain Name  C57BL/6JNifdc-Angptl4tm1(ANGPTL4)Bcgen/Bcgen
Common Name  B-hANGPTL4 mice plus
Background C57BL/6J Catalog number 112746
Aliases 

ARP4, FIAF, HARP, HFARP, NL2, PGAR, TGQTL, UNQ171, pp1158

mRNA expression analysis

from clipboard


Strain specific analysis of ANGPTL4 gene expression in wild-type mice and B-hANGPTL4 mice plus by RT-PCR. Mouse Angptl4 mRNA was detectable in fat of wild-type mice (+/+). Human ANGPTL4 mRNA was detectable in heterozygous B-hANGPTL4 mice plus but not in wild-type mice.


Protein expression analysis in serum


from clipboard

Strain specific ANGPTL4 expression analysis in homozygous humanized B-hANGPTL4 mice plus by ELISA. Serum was collected from homozygous B-hANGPTL4 mice plus (H/H) (n=1). Protein expression level of ANGPTL4 was analyzed by ELISA. Human ANGPTL4 was detectable in homozygous B-hANGPTL4 mice plus (H/H). 

Inhibitory efficiency of the nucleic acid drugs against the ANGPTL4 mRNA expression level

from clipboard

The inhibitory efficiency of the nucleic acid drugs against human ANGPTL4 mRNA in liver tissue in B-hANGPTL4 mice plus. B-hANGPTL4 mice plus were randomly divided into two groups (n=3/group, 8 weeks old). The human ANGPTL4 targeted nucleic acid drugs (Provided by the client) and PBS were administered to the mice individually. The nucleic acid drugs was administered in the form of PBS aqueous solution. The drug dosages for all animals were calculated according to the body weight. The mice were sacrificed on day 7, and the liver tissue was collected to detect the expression level of human ANGPTL4 mRNA by qPCR. (A) The schematic diagram of experimental processing. (B) The expression of human ANGPTL4mRNA in liver after treatment. The inhibition rate in the treatment group was 66.7% (The data comes from the client). The human ANGPTL4 in the treatment group (G2) was reduced compared to the control group (G1), demonstrating that B-hANGPTL4 mice plus provide a powerful preclinical model for in vivo evaluation of human ANGPTL4 targeted nucleic acid drugs. Values are expressed as mean ± SEM.